Abgenix And Agensys Enter Technology License Collaboration To Discover And Develop Human Therapeutic Antibodies Against Cancer
15-Aug-2001 -
Abgenix, Inc. (Nasdaq: ABGX) and Agensys, Inc., a
privately-held biotechnology company, announced today a research collaboration, option and license agreement under which the
parties will use Abgenix’s human antibody technologies to discover and develop fully human monoclonal antibody ...
antibodies
antigens
biotechnology
+9